These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36940110)

  • 21. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
    Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
    Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
    Tan E; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
    [No Abstract]   [Full Text] [Related]  

  • 23. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer.
    Chen Y; Liu C; Zhu S; Liang X; Zhang Q; Luo X; Yuan L; Song L
    Int Immunopharmacol; 2021 Jul; 96():107607. PubMed ID: 33831809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism and strategies of immunotherapy resistance in colorectal cancer.
    Shan J; Han D; Shen C; Lei Q; Zhang Y
    Front Immunol; 2022; 13():1016646. PubMed ID: 36238278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathological complete response after neoadjuvant immunotherapy combined with chemotherapy in pediatric rectal carcinoma: A case report.
    Cao X; Luo J; Zhao B; Fu H; Kang W
    Front Immunol; 2022; 13():1036181. PubMed ID: 36544760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Towards exertion of immunotherapeutics in the treatment of colorectal cancer; adverse sides, challenges, and future directions.
    Pan W; Zhao J; Zhang S; Chen X; Liang W; Li Q
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108337. PubMed ID: 34775366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
    Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171
    [No Abstract]   [Full Text] [Related]  

  • 28. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation.
    Wang Q; Shen X; Chen G; Du J
    Int J Cancer; 2023 Aug; 153(4):709-722. PubMed ID: 36752642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
    Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
    Front Immunol; 2022; 13():913483. PubMed ID: 35958603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An update on the use of immunotherapy in patients with colorectal cancer.
    Nguyen M; Tipping Smith S; Lam M; Liow E; Davies A; Prenen H; Segelov E
    Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):291-304. PubMed ID: 33138649
    [No Abstract]   [Full Text] [Related]  

  • 33. Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance.
    Abushukair H; Ababneh O; Zaitoun S; Saeed A
    Cancer Treat Res Commun; 2022; 33():100643. PubMed ID: 36175334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome of Patients With Early-Stage Mismatch Repair Deficient Colorectal Cancer Receiving Neoadjuvant Immunotherapy: A Systematic Review.
    Chakrabarti S; Grewal US; Vora KB; Parikh AR; Almader-Douglas D; Mahipal A; Sonbol MBB
    JCO Precis Oncol; 2023 Aug; 7():e2300182. PubMed ID: 37595183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
    Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer.
    Mahadevia H; Uson Junior PLS; Wang J; Borad M; Babiker H
    Expert Opin Pharmacother; 2024; 25(1):79-90. PubMed ID: 38193476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current advancements and future perspectives of immunotherapy in colorectal cancer research.
    Kishore C; Bhadra P
    Eur J Pharmacol; 2021 Feb; 893():173819. PubMed ID: 33347822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer.
    Li S; Na R; Li X; Zhang Y; Zheng T
    Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188758. PubMed ID: 35809762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
    Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
    Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.